Decellularized allografts as an alternative for reconstruction of large inferior alveolar nerve defects: a systematic review

Background: Inferior alveolar nerve (IAN) injuries are a clinical problem with devastating consequences, causing temporary or permanent paresthesia, significantly affecting the patient's quality of life. Despite morbidity, side effects and controversy regarding its results, autologous nerve grafting is still the main treatment for these type of lesions. However, due to advances in knowledge about nerve damage and with the aim of preventing the described problems of autografts, new treatment alternatives based on decellularized allografts have emerged. The aim of this systematic review was to evaluate the reported efficacy of decellularized allografts for the treatment of IAN damage.Material and Methods: We performed a systematic search in Pubmed, Scopus and Web of Science databases following the PRISMA guidelines. Cohort studies, randomized or non-randomized clinical studies, prospective or retrospective studies, without age limits and language restriction that included human subjects who received decellularized allograft as treatment for IAN damage were included. Results: Six articles met the inclusion criteria and were included for data analysis. In all 6 articles, resolution of IAN damage was observed in more than 85% of patients after a 12-month follow-up period, and in 2 of them, complete resolution was observed in 100% of their patients at longer follow-ups.Conclusions: Decellularized allograft appears to be a promising alternative to resolve IAN lesions, without re-quiring a nerve autograft procedure. However, more randomized clinical trials are needed to validate adequate treatment modalities with decellularized allografts.

Automated summary

This systematic review aimed to evaluate the efficacy of decellularized allografts for the treatment of inferior alveolar nerve (IAN) damage. The results showed that in all six articles, more than 85% of patients achieved resolution of IAN damage after a 12-month follow-up, and in two articles, complete resolution was observed in 100% of patients at longer follow-ups.